Regenxbio Inc. income statement

In fiscal 2025, Regenxbio Inc. reported revenue of $170m, up 104.5% on the year before, operating income of −$161m (a -94.6% margin) and net income of −$194m, or −$3.76 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Regenxbio Inc.: income statement, annual
Fiscal year	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	6	6	8	5	10	219	35	155	470	113	90	83	170	174
Cost of revenue	—	—	—	—	2	10	8	36	52	55	37	34	—	—
Gross profit	—	—	—	—	9	209	27	119	419	58	53	50	—	—
Research and development	5	5	17	45	57	84	124	166	181	242	232	209	228	229
General and administrative	5	4	12	24	27	37	52	64	79	85	88	77	83	86
Operating income	−5	−4	−23	−65	−76	88	−149	−119	160	−263	−268	−233	−161	−164
Interest expense	1	0	0	—	—	—	—	1	26	23	7	13	45	42
Provision for credit losses	—	—	—	—	—	—	—	—	—	—	—	−5	—	—
Income before tax	—	−4	−23	−63	−73	104	−97	−106	141	−280	−264	−227	−194	—
Income tax	0	0	0	−0	0	4	−3	5	13	−0	−0	0	0	—
Net income	−5	−4	−23	−63	−73	100	−95	−111	128	−280	−263	−227	−194	−196
Diluted EPS	−$0.83	−$0.61	−$0.86	−$2.38	−$2.45	$2.73	−$2.58	−$2.98	$2.91	−$6.50	−$6.02	−$4.59	−$3.76	−$3.76
Diluted shares (average)	7m	8m	28m	26m	30m	37m	37m	37m	44m	43m	44m	50m	52m	52m
EBITDA	−5	−4	−23	−65	−73	92	−142	−111	170	−250	−251	−217	−146	−149

US$ millions unless shown otherwise. Fiscal quarters.

Regenxbio Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	24	21	89	21	30	30	6	108
Cost of revenue	12	6	—	—	—	—	—	—
Gross profit	12	15	—	—	—	—	—	—
Research and development	54	50	53	60	56	60	57	56
General and administrative	19	20	20	20	20	22	21	22
Operating income	−62	−51	12	−63	−52	−58	−83	29
Interest expense	1	9	9	11	13	12	9	8
Net income	−60	−51	6	−71	−62	−67	−90	23
Diluted EPS	−$1.17	−$1.00	$0.12	−$1.38	−$1.20	−$1.30	−$1.72	$0.43
EBITDA	−58	−47	16	−59	−49	−54	−80	33

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NUVB vs RGNX ABUS vs RGNX IBRX vs RGNX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Regenxbio Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Regenxbio Inc.